<DOC>
	<DOC>NCT00543426</DOC>
	<brief_summary>The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM). The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.</brief_summary>
	<brief_title>Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Clinical diagnosis of B Post hepatitic cirrhosis. Male or female patients between 18~65 years old. Written informed consent. ChildPugh C above 12, or ALT &gt; 2×ULN, TBiL &gt; 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepatorenal syndrome, or primary liver cancer. Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease. Deformed man by the law. Pregnancy or breast feeding women, or unwilling to have contraception. Irritability body constitution, or irritability of the Fuzheng Huayu Capsules. Enter other trials lately one month. Other cause of cirrhosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Fuzheng Huayu Tablets</keyword>
	<keyword>Multicenter clinical study</keyword>
</DOC>